Cut Stack 150 mg/ml – HilmaBioCare EU

Product Overview & Pharmaceutical Specifications

Cut Stack is described in the supplied product information as an injectable, oil-based sterile solution containing three active ingredients: testosterone propionate, trenbolone acetate and drostanolone propionate.

Product Specifications

• Product name: Cut Stack
• Strength: 150 mg/ml
• Active pharmaceutical ingredients (APIs):
  • Testosterone propionate — 50 mg
  • Trenbolone acetate — 50 mg
  • Drostanolone propionate — 50 mg
• Dosage form: Injectable, oil-based sterile solution
• Route: Injection
• Pack size: 10 ml
• Packaging: Multiple-dose vial
• CAS number supplied: 434-22-0
• Molecular formula supplied: C17H19N5
• Molecular mass supplied: 322.1023 g/mol
• Manufacturer/company: Hilma Biocare
• Market status supplied: Prescription
• Storage: Store in a cool, dry place between 15–25°C. Protect from light.

Pharmacology & Product Information

Testosterone Propionate

The supplied documentation describes testosterone propionate as an androgen with both anabolic and androgenic properties. It states that testosterone propionate is designed to reach peak serum testosterone levels within approximately 24 hours following intramuscular administration, with levels remaining elevated for approximately 2–3 days.

The source describes testosterone supplementation in the context of hypogonadism and other disorders associated with androgen deficiency. It also states that testosterone has been associated with increases in strength, new muscle tissue and libido.

Trenbolone Acetate

Trenbolone acetate is described in the supplied information as an anabolic steroid with significant anabolic and androgenic properties.

The source states that its fast-acting ester produces a rapid increase in serum trenbolone levels, which remain elevated for several days thereafter. The supplied documentation also describes reported pharmacological effects involving muscle anabolism, strength, appetite and aggression.

These statements represent information contained in the supplied source and should not be interpreted as guaranteed clinical outcomes.

Drostanolone Propionate

The supplied documentation describes drostanolone propionate as a synthetic derivative of dihydrotestosterone (DHT).

According to the source, drostanolone has anabolic and androgenic properties and is described as promoting protein synthesis and a positive nitrogen balance. The supplied information states that, as a DHT derivative, drostanolone does not aromatize to estrogens.

The source further describes drostanolone as having an estrogen-antagonist effect and associates it with increased strength and muscle tissue development.

Ester Characteristics

The supplied product description refers to propionate esters and describes rapid increases in serum concentrations followed by sustained activity. It specifically states a duration of approximately 5–8 days in relation to drostanolone.

The source contains an inconsistency, referring to a combination of a short-acting propionate ester with a long-acting enanthate ester, although enanthate is not listed among the three active ingredients in the stated composition. No enanthate ingredient has therefore been added to the product specifications.

Adverse Reactions & Safety Information

The supplied product documentation reports the following adverse reactions and potential effects.

Male Reproductive Effects

• Gynecomastia
• Excessive frequency and duration of penile erections
• Oligospermia

Skin & Appendages

• Hirsutism
• Male-pattern baldness
• Acne
• Gynecomastia

Fluid & Electrolyte Disturbances

• Retention of sodium
• Retention of chloride
• Retention of water
• Retention of potassium
• Retention of calcium
• Retention of inorganic phosphates

Gastrointestinal & Hepatic Effects

• Nausea
• Cholestatic jaundice
• Alterations in liver function tests
• Rarely, hepatocellular neoplasms
• Peliosis hepatitis
• Hepatic adenomas
• Cholestatic hepatitis

Hematologic Effects

The supplied information reports suppression of clotting factors II, V, VII and X and notes the potential for bleeding in patients receiving anticoagulant therapy.

Nervous System Effects

Reported effects include:

• Increased or decreased libido
• Headache
• Anxiety
• Depression
• Generalized paresthesia

Other Reported Effects

• Serum lipid changes
• Hypercalcaemia
• Hypertension
• Oedema
• Priapism
• Potentiation of sleep apnea

Contraindications

The supplied product information lists the following contraindications:

• Known hypersensitivity to any ingredient in the product
• Known or suspected carcinoma of the breast, testis or prostate
• Severe heart disease
• Liver disease
• Kidney disease
• History of epilepsy

The source states that products containing testosterone should not be used in women because they may cause virilization and fetal harm.

Precautions

The supplied documentation states that caution should be exercised when administering androgens to patients with a history of myocardial infarction or coronary artery disease because androgens may alter serum cholesterol concentrations.

Additional precautions supplied include:

• Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen therapy is started or stopped.
• Androgens may alter the metabolism of oral hypoglycaemic agents.
• Androgens may alter insulin sensitivity in patients with diabetes mellitus.
• Adjustment of insulin or other hypoglycaemic medication may therefore be required under appropriate medical supervision.

Patient Monitoring

The supplied product information recommends monitoring of:

• Serum cholesterol
• HDL
• LDL
• Triglycerides (TG)
• Haemoglobin
• Haematocrit
• Hepatic function tests, including AST and ALT
• Prostate-specific antigen (PSA)
• Total testosterone
• Free testosterone
• Bioavailable testosterone
• Dihydrotestosterone (DHT)
• Estradiol

The source states that male patients over 40 should undergo a digital rectal examination and PSA evaluation before androgen use.

Periodic prostate evaluations should continue during androgen therapy, particularly in patients experiencing difficulty with urination or changes in voiding habits.

Dosage & Administration

The supplied source states that the daily dosage for males is 150–450 mg and that the product is not recommended for women.

Because the source identifies the product as prescription and injectable, administration should follow the applicable official prescribing information and the instructions of a qualified healthcare professional. The supplied dosage information should not be interpreted as individualized medical advice.

Presentation & Storage

Presentation: Cut Stack 150 mg/ml, 10 ml multiple-dose vial.

Storage: Store in a cool, dry place between 15–25°C. Protect from light.

Scientific & Regulatory References

No PubMed references, DOI references, clinical-literature citations, manufacturer documents or official regulatory-source links were supplied with the product data.

Accordingly, no external scientific or regulatory references have been added.

The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization, national authorization number or regulatory approval status was supplied. Therefore, no EU-wide authorization claim is made here.

Pharmaceutical Terms & Compliance

Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.

Cut Stack is identified in the supplied source as a prescription product. Regulatory requirements, authorization status, dispensing conditions and legal availability may differ between European countries. No claim of EU-wide marketing authorization or approval is made based solely on the supplied product information.